Quick News Bit


Intrauterine Contraceptive Devices Market Size is projected to reach USD 3.95 billion by 2031, growing at a CAGR of 3.5%: Straits Research

Health
By Eli Pacheco
0





New York, United States, March 07, 2023 (GLOBE NEWSWIRE) — The intrauterine device, or IUD, is a small, T-shaped contraceptive implanted inside the uterus. Such methods of contraception are effective, convenient, and safe. Using an IUD to prevent pregnancy is generally considered safe. To achieve their contraceptive effect, IUDs cause localized inflammation. Chemicals released during the inflammatory response in the uterus are fatal to sperm. There could be repercussions for sperm’s capacity to fertilize eggs. These can be helpful even if you’ve already had an abortion. An intrauterine device is one of the most effective and low-risk ways to prevent pregnancy (IUD). Intrauterine contraceptive devices (IUDs) are medical devices that can prevent pregnancy after they have been implanted. These can last anywhere from three to ten years in length.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/intrauterine-contraceptive-devices-iud-market/request-sample 

An Increase in Awareness of These Devices’ Availability through Campaigns and Digital Advertisements Drives the Global Market

Small T-shaped devices called intrauterine devices (IUDs) are implanted in women’s uteruses to stop pregnancy. Hormonal contraceptives, such as copper IUDs, are very popular. The market for intrauterine contraceptives is growing due to the products’ many positive attributes. Government programs that emphasize the benefits of using IUDs have a significant impact on market demand. Even in developing countries, the need for these tools is the only reason for spreading the word about them. Intrauterine contraceptive devices are experiencing rapid market growth due to increasing demand and continuous innovation’s stimulating effect.

Increasing Inclination towards Planned Delayed Pregnancy Creates Tremendous Opportunities

Growth of the market is expected to be driven by rising demand from women who want to postpone having children voluntarily. The adoption of novel strategies by the United States government to increase access to sexual and reproductive health services and products is expected to increase the number of people interested in delaying pregnancy. In women, intrauterine devices prevent fertility for 3-10 years with a 99% success rate. In many parts of the country, teenage girls are rising. That means more women must have access to and use contraceptives like intrauterine devices to stop unwanted pregnancies and unsafe abortions. It has significant implications, in addition to the high product adoption rates for preventing unintended pregnancies. The far-reaching effects of unintended pregnancies are expected to increase market opportunities for IUDs in the coming years.

Report Scope

Report Metric Details
Market Size USD 3.95 billion by 2031
CAGR 3.5% (2023-2031)
Historical Data 2020-2021
Base Year 2022
Forecast Period 2023-2031
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, Product, End-User
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Agile Therapeutics, Bayer Healthcare, Fuji Latex Co. Ltd, Pfizer, Reckitt Benckiser Group PLC, Mylan Laboratories, Merck & Co., and Okamato Industries Inc.
Key Market Opportunities Increasing Inclination towards Planned Delayed Pregnancy
Key Market Drivers An Increase in Awareness of These Devices’ Availability through Campaigns and Digital Advertisements


Buy Now Full Report @ https://straitsresearch.com/buy-now/intrauterine-contraceptive-devices-iud-market

Regional Analysis

Europe is the most significant shareholder in the global intrauterine contraceptive devices market and is expected to grow during the forecast period.   Europe is expected to lead the market for intrauterine contraceptive devices due to the region’s high adoption of IUDs over oral contraceptives. Effective and relatively side-effect-free, intrauterine devices (IUDs) are a popular method of birth control. The fertility rate in Europe is the lowest of any continent. Across the region, the average number of children per family is 1.44. Manufacturers invest heavily in R&D to develop novel products with enhanced efficacy and reduced side effects (R&D). As a result of rising healthcare costs and personal preferences, consumers are increasingly putting off having children, which is expected to boost demand further.

Asia-Pacific is expected to grow during the forecast period. Because Asia and the Pacific have a higher rate of unintended pregnancy, it stands to reason that this region would have a disproportionately large share of the market for intrauterine contraceptive devices. The market expansion is also aided by the growing number of healthcare-related government initiatives in Asia. Government and non-government organizations have made strides in recent years to increase access to intrauterine contraceptive devices to decrease the number of abortions and unintended pregnancies.

There is an expected rise in the North American market for intrauterine contraceptive devices to the position of second largest in the world. Women are becoming increasingly aware of the issue, and IUDs are an effective and long-lasting solution. According to data from the National Center for Health Statistics, long-acting intrauterine devices (IUDs) are women’s most common form of contraception. Because they are one of the most effective forms of reversible contraception, UDs are gaining popularity among women and doctors. The highest levels of demand have been seen in the United States market for both hormone-free copper IUDs and IUDs that use hormones. Many American women use hormonal IUDs; three of the most popular brands are Mirena, Skyla, and Liletta. Patients’ access to IUDs has grown thanks to new recommendations from the American College of Obstetricians and Gynaecologists.

Slow development in LAMEA is likely due to low awareness and unfulfilled demand. The UN report found that 24% of the unmet need was in the countries of sub-Saharan Africa. The unmet need is usually the highest in areas where contraceptive use is low. Furthermore, most Latin American and Caribbean countries had relatively high rates of contraceptive use. The many benefits of intrauterine devices, such as their high efficacy as a method of birth control and their low impact on fertility and menstrual symptoms, have increased in popularity in recent years.

Key Highlights

  • The global intrauterine contraceptive devices market was valued at USD 2.89 billion in 2022. It is projected to reach USD 3.95 billion by 2031, growing at a CAGR of 3.5% during the forecast period (2023–2031).
  • Based on type, the global intrauterine contraceptive devices market is bifurcated into hormonal and copper intrauterine devices. The hormonal intrauterine devices segment is the highest contributor to the market and is expected to grow during the forecast period.
  • Based on product, the global intrauterine contraceptive devices market is bifurcated into Mirena, Skyla, paragard, essure, levosert, and others. The Mirena segment is the highest contributor to the market and is expected to grow during the forecast period.
  • Based on end-user, the global intrauterine contraceptive devices market is bifurcated into hospitals, gynecology clinics, and community healthcare centers. The hospital segment is the highest contributor to the market and is expected to grow during the forecast period.
  • Europe is the most significant shareholder in the global intrauterine contraceptive devices market and is expected to grow during the forecast period. 

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/intrauterine-contraceptive-devices-iud-market/request-sample

Competitors in Intrauterine Contraceptive Devices Market

The global intrauterine contraceptive devices market’s major key players are

  • Agile Therapeutics
  • Bayer Healthcare
  • Fuji Latex Co. Ltd
  • Pfizer
  • Reckitt Benckiser Group PLC
  • Mylan Laboratories
  • Merck & Co.
  • Okamato Industries Inc.

Segmentation of Intrauterine Contraceptive Devices Market

By Type

  • Hormonal Intrauterine Devices
  • Copper Intrauterine Devices

By Product

  • Mirena
  • Skyla
  • Paragard
  • Essure
  • Levosert
  • Others

By End-User

  • Hospitals
  • Gynecology Clinics
  • Community Healthcare Centers

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Table of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Market Definition
    3. Limitations & Assumptions
    4. Market Scope & Segmentation
    5. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    4. Investment Landscape
    5. New Business Models / Revenue Streams
    6. TAM
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Human Factors
    6. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    3. Sales And Distribution Channel Analysis
    4. Trade Analysis
    5. Average Pricing Analysis
    6. Patent Analysis
    7. M & A Agreements & Collabration Analysis
    8. Cost Structure Analysis
  6. ESG Trends
  7. Global Intrauterine Contraceptive Devices Market Size Analysis
    1. Global Intrauterine Contraceptive Devices Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hormonal Intrauterine Devices
        1. By Value
      3. Copper Intrauterine Devices
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Mirena
        1. By Value
      3. Skyla
        1. By Value
      4. Paragard
        1. By Value
      5. Essure
        1. By Value
      6. Levosert
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals
        1. By Value
      3. Gynecology Clinics
        1. By Value
      4. Community Healthcare Centers
        1. By Value
  8. North America Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hormonal Intrauterine Devices
        1. By Value
      3. Copper Intrauterine Devices
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Mirena
        1. By Value
      3. Skyla
        1. By Value
      4. Paragard
        1. By Value
      5. Essure
        1. By Value
      6. Levosert
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals
        1. By Value
      3. Gynecology Clinics
        1. By Value
      4. Community Healthcare Centers
        1. By Value
    5. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hormonal Intrauterine Devices
          1. By Value
        3. Copper Intrauterine Devices
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Mirena
          1. By Value
        3. Skyla
          1. By Value
        4. Paragard
          1. By Value
        5. Essure
          1. By Value
        6. Levosert
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals
          1. By Value
        3. Gynecology Clinics
          1. By Value
        4. Community Healthcare Centers
          1. By Value
    6. Canada
  9. Europe Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hormonal Intrauterine Devices
        1. By Value
      3. Copper Intrauterine Devices
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Mirena
        1. By Value
      3. Skyla
        1. By Value
      4. Paragard
        1. By Value
      5. Essure
        1. By Value
      6. Levosert
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals
        1. By Value
      3. Gynecology Clinics
        1. By Value
      4. Community Healthcare Centers
        1. By Value
    5. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hormonal Intrauterine Devices
          1. By Value
        3. Copper Intrauterine Devices
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Mirena
          1. By Value
        3. Skyla
          1. By Value
        4. Paragard
          1. By Value
        5. Essure
          1. By Value
        6. Levosert
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals
          1. By Value
        3. Gynecology Clinics
          1. By Value
        4. Community Healthcare Centers
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest Of Europe
  10. APAC Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hormonal Intrauterine Devices
        1. By Value
      3. Copper Intrauterine Devices
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Mirena
        1. By Value
      3. Skyla
        1. By Value
      4. Paragard
        1. By Value
      5. Essure
        1. By Value
      6. Levosert
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals
        1. By Value
      3. Gynecology Clinics
        1. By Value
      4. Community Healthcare Centers
        1. By Value
    5. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hormonal Intrauterine Devices
          1. By Value
        3. Copper Intrauterine Devices
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Mirena
          1. By Value
        3. Skyla
          1. By Value
        4. Paragard
          1. By Value
        5. Essure
          1. By Value
        6. Levosert
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals
          1. By Value
        3. Gynecology Clinics
          1. By Value
        4. Community Healthcare Centers
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest Of Asia-Pacific
  11. Middle East And Africa Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hormonal Intrauterine Devices
        1. By Value
      3. Copper Intrauterine Devices
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Mirena
        1. By Value
      3. Skyla
        1. By Value
      4. Paragard
        1. By Value
      5. Essure
        1. By Value
      6. Levosert
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals
        1. By Value
      3. Gynecology Clinics
        1. By Value
      4. Community Healthcare Centers
        1. By Value
    5. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hormonal Intrauterine Devices
          1. By Value
        3. Copper Intrauterine Devices
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Mirena
          1. By Value
        3. Skyla
          1. By Value
        4. Paragard
          1. By Value
        5. Essure
          1. By Value
        6. Levosert
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals
          1. By Value
        3. Gynecology Clinics
          1. By Value
        4. Community Healthcare Centers
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest Of MEA
  12. LATAM Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Hormonal Intrauterine Devices
        1. By Value
      3. Copper Intrauterine Devices
        1. By Value
    3. By Product
      1. Introduction
        1. Product By Value
      2. Mirena
        1. By Value
      3. Skyla
        1. By Value
      4. Paragard
        1. By Value
      5. Essure
        1. By Value
      6. Levosert
        1. By Value
      7. Others
        1. By Value
    4. By End-User
      1. Introduction
        1. End-User By Value
      2. Hospitals
        1. By Value
      3. Gynecology Clinics
        1. By Value
      4. Community Healthcare Centers
        1. By Value
    5. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Hormonal Intrauterine Devices
          1. By Value
        3. Copper Intrauterine Devices
          1. By Value
      2. By Product
        1. Introduction
          1. Product By Value
        2. Mirena
          1. By Value
        3. Skyla
          1. By Value
        4. Paragard
          1. By Value
        5. Essure
          1. By Value
        6. Levosert
          1. By Value
        7. Others
          1. By Value
      3. By End-User
        1. Introduction
          1. End-User By Value
        2. Hospitals
          1. By Value
        3. Gynecology Clinics
          1. By Value
        4. Community Healthcare Centers
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest Of LATAM
  13. Competitive Assessment
    1. Adoption Matrix
    2. Intrauterine Contraceptive Devices Market Share By Manufacturers
    3. Intrauterine Contraceptive Devices Market Ranking By Revenue For Manufacturers
    4. Average Price By Manufacturers
    5. Vendor Footprint Analysis
  14. Market Players Assessment
    1. Agile Therapeutics
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. Gross Margin
      6. Swot Analysis
      7. Recent Developmments
    2. Bayer Healthcare
    3. Fuji Latex Co. Ltd
    4. Pfizer
    5. Reckitt Benckiser Group PLC
    6. Mylan Laboratories
    7. Merck & Co.
    8. Okamato Industries Inc.
  15. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data From Secondary Sources
      2. Primary Data
        1. Key Data From Primary Sources
        2. Breakdown Of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  16. APPENDIX
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  17. DISCLAIMER

Table of Content and Figure @ https://straitsresearch.com/report/intrauterine-contraceptive-devices-iud-market/toc

Recent Development

  • In October 2022, Pfizer Inc. completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the developer of NURTEC ODT, a novel migraine therapy approved for both the acute treatment of migraine attacks and their prevention.
  • In September 2022, The CytoReason and Pfizer Collaboration Agreement were expanded to include the Provision of Artificial Intelligence for Drug Discovery and Development.

News Media

Intrauterine Contraceptive Devices (IUD) Market: Blocking Fertilization

Asia-Pacific Region Exhibiting the Fastest Growth in the Global Pregnancy Tracking Application Market

Have a Look at the Related Research Report

Women’s Health Care Market: Information by Drug (Vagifem, Lupron, and Yasmin), Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis), and Regional Insights till Forecast to 2031

Pregnancy Tracking Application Market: Information by Solution (Fertility Tracking), Deployment Type (Android System), Application (Private Users), and Region — Forecast till 2026

Fertility Test Market: Information by Product (Ovulation Prediction Kits, Fertility Monitors), Mode of Purchase (OTC-based, Prescription-based), Application, and Region — Forecast till 2030

Fertility Services Market: Information by Procedure (IVF with Intracytoplasmic Sperm Injection (ICSI), Surrogacy), Service (Fresh Non-Donor, Fresh Donor), and Region — Forecast till 2030

Maternity Wear Market: Information by Product Type (Outerwear, Innerwear, and Nightwear), Distribution Channel (Store-Based Retail, Convenience Stores), and Region — Forecast till 2029

About Straits Research Pvt. Ltd.

StraitsResearch is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: [email protected]

Follow Us: LinkedIn | Facebook | Instagram | Twitter

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News. 

Read original article here

Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Eli Pacheco 130626 posts 0 comments
Leave a comment